宏基因组分析揭示中国2型糖尿病患者肠道菌群与靶向胃肠道的降糖药物之间的相互作用:一项为期6个月的双臂随机试验
该研究为在北京开展的随机、开放标签、双臂试验,纳入100例超重/肥胖新诊断2型糖尿病患者,随机接受阿卡波糖(n=50)或维格列汀(n=50)单药治疗6个月,最终92例纳入分析。两药均显著降低HbA1c和内脏脂肪面积,并引起药物特异性和共享的肠道菌群变化,基线肠道菌群与维格列汀的GLP-1反应强烈相关。
要点
- 阿卡波糖和维格列汀单药治疗6个月均显著降低HbA1c和内脏脂肪面积。
- 两药引起药物特异性及共享的肠道菌群变化,尤其拟杆菌门物种共同减少。
- 基线肠道菌群而非基线GLP-1水平与维格列汀的GLP-1反应强烈相关。
核心结论
- 研究揭示两种以不同方式靶向肠道的降糖药在2型糖尿病患者中引起共同的微生物反应,基线肠道菌群对区分维格列汀不同GLP-1反应个体具有可接受的性能。
- 研究结果强调肠道菌群与降糖药物之间的双向相互作用。
研究设计与样本
- 随机、开放标签、双臂试验,2016年12月至2017年12月在北京开展。
- 从Pinggu医院招募100例超重/肥胖新诊断2型糖尿病患者,采用密封信封随机分配至阿卡波糖组(n=50)或维格列汀组(n=50),治疗6个月。
- 治疗前后收集血液、粪便样本及CT图像的内脏脂肪数据,并下载处理既往2型糖尿病队列接受阿卡波糖或格列吡嗪治疗3个月的宏基因组数据集。
- 最终92例参与者纳入分析(阿卡波糖组n=44,维格列汀组n=48)。
主要发现
- 阿卡波糖组HbA1c从60 mmol/mol(7.65%)降至46 mmol/mol(6.40%),维格列汀组从59 mmol/mol(7.55%)降至44 mmol/mol(6.20%),两组内脏脂肪面积均显著降低(治疗前后比较校正P值均<0.05)。
- 两组均出现多种肠道微生物物种和通路的药物特异性及共享相对丰度变化,尤其拟杆菌门物种共同减少。
- 两项独立研究中,阿卡波糖治疗3个月和6个月引起的微生物组成变化高度相似。
- 维格列汀治疗显著提高空腹活性胰高血糖素样肽-1(GLP-1)水平。
- 基线肠道菌群而非基线GLP-1水平与维格列汀的GLP-1反应强烈相关,与阿卡波糖的GLP-1反应关联较弱。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The use of oral glucose-lowering drugs, particularly those designed to target the gut ecosystem, is often observed in association with altered gut microbial composition or functional capacity in individuals with type 2 diabetes. The gut microbiota, in turn, plays crucial roles in the modulation of drug efficacy. We aimed to assess the impacts of acarbose and vildagliptin on human gut microbiota and the relationships between pre-treatment gut microbiota and therapeutic responses. METHODS: This was a randomised, open-labelled, two-arm trial in treatment-naive type 2 diabetes patients conducted in Beijing between December 2016 and December 2017. One hundred participants with overweight/obesity and newly diagnosed type 2 diabetes were recruited from the Pinggu Hospital and randomly assigned to the acarbose (n=50) or vildagliptin (n=50) group using sealed envelopes. The treatment period was 6 months. Blood, faecal samples and visceral fat data from computed tomography images were collected before and after treatments to measure therapeutic outcomes and gut microbiota. Metagenomic datasets from a previous type 2 diabetes cohort receiving acarbose or glipizide for 3 months were downloaded and processed. Statistical analyses were applied to identify the treatment-related changes in clinical variables, gut microbiota and associations. RESULTS: Ninety-two participants were analysed. After 6 months of acarbose (n=44) or vildagliptin (n=48) monotherapy, both groups achieved significant reductions in HbA1c (from 60 to 46 mmol/mol [from 7.65% to 6.40%] in the acarbose group and from 59 to 44 mmol/mol [from 7.55% to 6.20%] in the vildagliptin group) and visceral fat areas (all adjusted p values for pre-post comparisons <0.05). Both arms showed drug-specific and shared changes in relative abundances of multiple gut microbial species and pathways, especially the common reductions in Bacteroidetes species. Three months and 6 months of acarbose-induced changes in microbial composition were highly similar in type 2 diabetes patients from the two independent studies. Vildagliptin treatment significantly enhanced fasting active glucagon-like peptide-1 (GLP-1) levels. Baseline gut microbiota, rather than baseline GLP-1 levels, were strongly associated with GLP-1 response to vildagliptin, and to a lesser extent with GLP-1 response to acarbose. CONCLUSIONS/INTERPRETATION: This study reveals common microbial responses in type 2 diabetes patients treated with two glucose-lowering drugs targeting the gut differently and acceptable performance of baseline gut microbiota in classifying individuals with different GLP-1 responses to vildagliptin. Our findings highlight bidirectional interactions between gut microbiota and glucose-lowering drugs. TRIAL REGISTRATION: ClinicalTrials.gov NCT02999841 FUNDING: National Key Research and Development Project: 2016YFC1304901.
引用
- Zhang X, Ren H, Zhao C, et al. Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial. Diabetologia. 2022. PMID: 35930018. doi:10.1007/s00125-022-05768-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。